RecruitingPhase 3NCT07253688

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)

Sponsor

Todd C. Lee MD MPH FIDSA

Enrollment

330 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Prosthetic Valve Endocarditis Staphylococcus Aureus Endocarditis

Summary

This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying No rifampin and a drug called Rifampin for people with prosthetic valve endocarditis and staphylococcus aureus endocarditis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRifampin

Patients will receive rifampin 900mg a day in 2-3 divided doses

OTHERNo rifampin

Subjects will be assigned to not receive adjunctive rifampin

Locations(1)

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07253688

Related Trials

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

NCT0663733218 locations

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT048862846 locations

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT066504881 location

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT066505011 location

Evolution of PET Fixation With FDG at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis

NCT059891521 location